Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: investigational agents for chronic hepatitis C

(2009) A. J. V. THOMPSON et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C

(2009) Maribel Rodriguez-Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY